Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Filanesib + Carfilzomib in Advanced Multiple Myeloma
NCT01989325Phase 2Completed
- Sponsor
- Pfizer
- Start
- Nov 2013
- Primary completion
- Feb 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of filanesib in multiple myeloma (MM) (2 arms), sponsored by Pfizer. Primary endpoint: Progression-Free Survival at 18 months. Started Nov 2013; status: completed.
02
Drugs
filanesib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT01989325.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01989325.